Bristol Evaluation of Airways Diagnostics & Therapies Outcomes
Research type
Research Study
Full title
BRistol Evaluation of novel Airways diagnostics, Therapies & Healthcare outcomEs: BREATHE study
IRAS ID
321349
Contact name
James Dodd
Contact email
Sponsor organisation
North Bristol NHS Trust
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Airways disease describes a group of conditions primarily consisting of asthma and chronic obstructive pulmonary disease (COPD). 5.4 million people suffer from asthma in the UK and COPD admissions account for over 1 million hospital bed days and 30,000 deaths. They are also among the most costly chronic diseases, with the annual costs of COPD £1.9 billion and asthma £3 billion. Airways disease disproportionately effects lower socioeconomic groups and this group of patients represent an extremely vulnerable and underrepresented group in British healthcare with a significant burden of morbidity and mortality.
The BREATHE study is a longitudinal cohort study, using routinely collected data, that will assess treatable and non-treatable traits of patients with confirmed or suspected airways disease both during exacerbation and at stable state. Participants will be recruited directly from the Complex Airways Clinic. The BREATHE study will then record data from the initial clinic appointment, at 6, 12 and 24 months after recruitment. This 2-year data collection method will ensure key data points and outcomes are captured. Each pathway will record data for a maximum of 24 months. During an exacerbation we may see the patient on day 0, 7 and 14 via our Airways urgent clinic as part of their routine clinical care. As part of our first sub-study (BREATHE-ILO) we will assess the prevalence of asthma ‘mimics’ including inducible laryngeal obstruction which is a considerable burden in terms of non-asthma morbidity and drain on healthcare.
BREATHE does not intend to conduct any additional sampling or data collection that will not be part of a patients clinical care. The adaptive nature of this study will allow for changes (with ethical approval) to the protocol with the emergence of novel diagnostics and therapies so that our objectives can be met whilst the landscape of airways medicine changes.REC name
London - Westminster Research Ethics Committee
REC reference
23/LO/0279
Date of REC Opinion
12 May 2023
REC opinion
Further Information Favourable Opinion